|Bid||9.91 x 0|
|Ask||10.01 x 0|
|Day's Range||9.91 - 10.18|
|52 Week Range||5.45 - 16.44|
|Beta (5Y Monthly)||1.35|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 28, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||21.70|
Immunicum AB (publ; IMMU.ST) announced today that the final data analysis from the clinical study of ilixadencel in patients with Gastrointestinal Stromal Tumors (GIST) has been published in the journal, Cancer Immunology, Immunotherapy. GIST is a rare and difficult-to-treat disease indication and the trial met the primary endpoint of safety showing that ilixadencel in combination with different tyrosine kinase inhibitors (TKIs) had a favorable safety profile with no treatment-related serious adverse events and no signs of autoimmunity.
Immunicum AB (publ; IMMU.ST) announced today that the sixth patient has completed the safety period in the ongoing Phase Ib/II ILIAD combination trial with ilixadencel, the Company’s cell-based, off-the-shelf immune primer for the treatment of solid tumors. The Dose Escalation Committee (DEC) confirmed there were no dose limiting toxicities, therefore the study can move into the non-staggered inclusion phase. The Phase Ib portion of the ILIAD trial is evaluating the safety and tolerability of Immunicum’s lead candidate, ilixadencel, in combination with the checkpoint inhibitor (CPI) Keytruda® (pembrolizumab) in 21 patients.
Press Release 13 May 2020 Immunicum AB (publ) Announces Appointment of Peter Hein as Interim Chief Financial Officer Immunicum AB (publ; IMMU.ST) announced today that Peter.
Immunicum AB (publ; IMMU.ST) announced today that it has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) for the Company’s lead candidate, ilixadencel, a cell-based, off-the-shelf immune primer for the treatment of metastatic Renal Cell Carcinoma (mRCC). The FDA’s decision was made based on the previously communicated results from the Phase II MERECA clinical trial that evaluated the safety and efficacy of ilixadencel in combination with Sutent® (sunitinib) in patients with newly diagnosed mRCC.
For more detailed information regarding the contents of the resolutions, please refer to the notice to the AGM and the complete proposals, which have previously been published and are available on the Company’s website, www.immunicum.com. The AGM adopted the Company’s balance sheet and income statement. The AGM resolved that the Company’s accumulated losses shall be appropriated so that SEK 134,015,842 is settled against the share premium reserve and that the remaining SEK 268,167,921 is carried forward and that no dividends shall be paid for the financial year 2019.
Earnings and diluted earnings per share totaled SEK -0.3 (-0.3). Immunicum AB Presented Updated Data from Phase II. December 2019 data showed a separation in survival curves in favor of the ilixadencel group.
Press Release 3 April 2020 Immunicum AB (publ) Publishes the Annual Report for 2019 Immunicum AB (publ; IMMU.ST), today announced that its Annual Report for 2019 is.
Press Release 30 March 2020 Immunicum AB (publ) Announces Peter Suenaert to Resume Role as Chief Medical Officer Immunicum AB (publ) announced today that Peter Suenaert,.
Press Release 27 March 2020 Notice of Annual General Meeting in Immunicum AB (publ) The shareholders of Immunicum AB (publ) (the “Company”), reg. no 556629-1786, are.
Immunicum AB (publ) announces that the company's CFO, Michaela Gertz, today announced that she has decided to leave the company at her own request. Michaela has been an important partner for me over the years, especially in recent months.
Press Release 6 February 2020 Immunicum AB (publ) Presents Updated Data from Phase II MERECA Trial of Ilixadencel in Kidney Cancer at ASCO-SITC Clinical Immuno-Oncology.
Press Release 3 February 2020 Immunicum AB (publ) Announces Publication of Abstracts for the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium Immunicum AB (publ; IMMU.ST).
Press Release 20 December 2019 Immunicum AB (publ) Announces Upcoming Oral Presentation on MERECA Trial at the ASCO-SITC Clinical Immuno-Oncology Symposium Immunicum AB.
The Board of Directors of Immunicum announced today that, by mutual agreement, Carlos de Sousa has resigned as CEO of Immunicum effective immediately. The Board has appointed Alex Karlsson-Parra, Immunicum’s Chief Scientific Officer, as acting CEO. Over the past three years as CEO, Carlos has significantly contributed to steering the company through a demanding phase in the development of the drug candidate ilixadencel.
Even if it's not a huge purchase, we think it was good to see that Margareth Jorvid, the Head of Regulatory affairs...
If you own shares in Immunicum AB (publ) (STO:IMMU) then it's worth thinking about how it contributes to the...
Immunicum announced the topline data from the exploratory Phase II MERECA clinical trial. Immunicum AB Announced Advancement to Next Dosage Group Level in Phase Ib/II ILIAD Combination Trial. Immunicum AB Announced Positive Preclinical Data on Ilixadencel in Combination with CTLA-4 Immune Checkpoint Inhibitor.
Press Release 21 October 2019 Immunicum AB (publ) Announces Positive Preclinical Data on Ilixadencel in Combination with CTLA-4 Immune Checkpoint Inhibitor Immunicum AB.
Immunicum AB (publ) in accordance with the principles of appointing the Nomination Committee, adopted by the Annual General Meeting of April 25, 2019, announced today that the members of the Nomination Committee have been appointed. The Nomination Committee for Immunicum shall be appointed by the four largest shareholders as of August 31, 2019 that have accepted the invitation to participate in the committee.
If you want to know who really controls Immunicum AB (publ) (STO:IMMU), then you'll have to look at the makeup of its...
Press Release 1 October 2019 Immunicum AB (publ) Announces Advancement to Next Dosage Group Level in Phase Ib/II ILIAD Combination Trial Immunicum AB (publ) announced.
Press Release 25 September 2019 Immunicum AB (publ) Announces Complete Topline Data Analysis from Phase II MERECA Trial --Survival as of July 2019 was 57% (32 out of 56).
Press Release 29 August 2019 Immunicum AB (publ) Announces Positive Phase II MERECA Topline Results Including Complete Tumor Responses in Metastatic Renal Cell Carcinoma.
Earnings and diluted earnings per share totaled SEK -0,4 (-0,4). Immunicum announced positive topline results from its completed Phase I/II clinical trial examining the safety and tolerability of Immunicum’s lead candidate, ilixadencel, in combination with tyrosine kinase inhibitors (TKIs) in six patients with Gastrointestinal Stromal Tumors (GIST), a rare and difficult-to-treat disease indication.